Medicare Add-On Payments For CAR-T Should Reflect 80% Of Actual Costs, CMS Told

Biopharma firms and providers argue that CMS's current approach to awarding Medicare new technology add-on payments for CAR-T treatment is not suited to the high-cost therapy and is leading some hospitals to mark up billed charges substantially so they can get as much supplemental reimbursement as possible.